Deep Tech Pioneers Mesh Bio Revolutionizing Chronic Disease Management with AI and Digital Twins

Mesh Bio: The Role of Deep Tech in Modern Healthcare

What if we could prevent catastrophic diseases like cardiovascular disease, diabetes, and stroke with advancements brought by deep tech? Emerging since 2014, the term deep tech describes companies that focus on substantial scientific or engineering breakthroughs med at tackling global challenges. While most digital startups are about creating new products or business concepts, deep tech startups delve into complex areas such as biotechnology, robotics and blockchn. These organizations have the potential to spark change, establish new industries, and disrupt existing ones, as highlighted in Deep Tech: The New Wave publications.

Healthcare is an area where deep tech directly impacts lives through medical innovation. According to the Future Health Index 2024 report, healthcare leaders are already implementingfor clinical decision support across various hospital departments including in-hospital monitoring, medication management, treatment planning, radiology, and preventative care.

To explore howimplementation affects healthcare delivery further, we spoke with Dr. Andrew Wu, Co-Founder and Chief Executive Officer of Mesh Bio, a Singapore-based deep tech startup ming to address chronic disease management through predictive analytics.

Transforming Chronic Disease Management

Predictive analysis at an individual level enhances patient care, empowers health management, reduces administrative tasks for medical professionals, and improves public health strategies and policies.

Mesh Bio is pioneering an innovative approach toward personalized healthcare scale-up by leveraging its DARA Health Intelligence Platform. This platform enables the integration of multidimensional patient data, utilizes advanced analytics including digital twin technology, and provides actionable insights to doctors, generating tlored recommations for patient care.

The company's efforts in Singapore have progressed through partnerships with SingHealth and NHG under the I2A grant, deploying their HealthVector Diabetes model into public healthcare systems.

Mesh Bio’s pioneering Foundation Digital Twin Model: HealthVector Diabetes

HealthVector Diabetes is recognized as the world's first foundational digital twin of biology that has achieved regulatory approval from Singapore's Health Science Authority and validation in a clinical paper published by Nature Digital Medicine journal, the first for the country.

In recent months, Mesh Bio has expanded its regional reach through agreements with three new healthcare providers in Indonesia and launched operations in the Philippines alongside Fullerton Health.

Mesh Bio’s Commitment to Healthcare Innovation

The rise of GenerativeGen holds significant promise to transform healthcare by improving patient care outcomes. Dr. Wu expressed his excitement about integrating Gen into their clinical analytics engine while combining it with Mesh Bio's foundational digital twin model, HealthVector Diabetes.

These innovations are deeply rooted in Mesh Bio’s mission to become the leading global health technology company where digital twin technology enables precision medicine, facilitating targeted interventions for patients and delivering personalized care at scale.

As part of East Ventures' ecosystem since 2023, Mesh Bio is now poised to build momentum in key markets such as Indonesia, Malaysia, and the Philippines by elevating healthcare standards.

However, digital transformation remns nascent in Southeast Asia, with educating the market on the value these solutions can create being Mesh Bio's biggest challenge.

East Ventures has been actively investing in healthtech startups to address Indonesia’s greatest challenges, focusing on prevention, early detection, and effective treatment accessibility.

In the coming decade, East Ventures anticipates that technology integration into healthcare will present numerous significant opportunities for Southeast Asia. A recent study indicates a shift from telehealth investments towards biotech ones.

If you're a startup founder building in the healthcare sector, consider sing us your pitch.

---

Copyright ? 2024 East Ventures All Rights Reserved
This article is reproduced from: https://east.vc/news/from-portfolios/mesh-bio-the-role-of-deep-tech-in-healthcare/

Please indicate when reprinting from: https://www.623n.com/Plastic_surgery_hospital/Deep_Tech_Healthcare_Innovation_Mesh_Bio.html